The Burden of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In France: A Comparison With The European Results From The Ibis-C Observational Study

Coffin, Benoït; Follet, Mathieu; Mackinnon, J; Bertsch, Jordan; Fortea, J; Tack, Jan

doi:10.1016/j.jval.2015.09.2237

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This includes the cost of medication, diagnostic tests, hospitalisations, medical consultations with specialists and nurses, and medical consultations with general/family doctors. 20 In the UK it has been calculated that IBS accounts for about 0.1% of the total National Health Service cost. 12 Interestingly, it is estimated that the total cost (direct and indirect) of IBS is comparable to that of other long-term diseases with a similar prevalence, such as asthma, migraine, hypertension or congestive heart failure.…”

Section: The Burden Of Ibs On Healthcare Systemsmentioning

confidence: 99%

The global impact of IBS: time to think about IBS-specific models of care?

Corsetti

Whorwell

2017

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal (GI) disorder that can significantly erode the quality of life (QoL) of sufferers and places a major cost burden on healthcare services. This paper reviews the literature on the impact of IBS on healthcare services and society, including a recent report on the subject, in order to formulate a plan for the future. A completely different model of care for these patients is recommended based on this review and the experience of the two authors who have been treating patients with functional GI disorders for 20 and 35 years, respectively.

show abstract

Section: The Burden Of Ibs On Healthcare Systemsmentioning

confidence: 99%

The global impact of IBS: time to think about IBS-specific models of care?

Corsetti

Whorwell

2017

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…6 Mean overall costs for IBS-C in a United States (US) community center analysis were US$11,406 over a 2-year period, and in Europe, the mean annual overall costs to the healthcare system for moderate-tosevere IBS-C were €4639. 7,8 While some patients with IBS-C may experience mild or intermittent symptoms, for some, these symptoms are severe and debilitating. IBS is also associated with a significant GI and non-GI comorbidity burden, 9 which contributes to the significant impact of IBS-C on patients' healthrelated quality of life.…”

Section: Introductionmentioning

confidence: 99%

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms

Serrano-Falcón

Delgado-Aros

Mearin

et al. 2019

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient population. Methods: In this open-label phase IIIb study, patients with moderate-to-severe IBS-C received linaclotide 290 μg once daily for 12 weeks. The primary endpoint was clinical response at week 12, defined as >30% reduction in IBS symptom severity score (IBS-SSS) or IBS-SSS <75 plus self-reported response of feeling ‘better’ or ‘much better’ versus the baseline. Digestive nonintestinal and extra-digestive symptom scores were assessed. Baseline characteristics and week 4 clinical response were assessed as predictors of week 12 clinical response. Results: A total of 96 patients were eligible; 91 were female and the mean age was 47.4 years. Mean (SD) baseline IBS-SSS was 371 (72.5). In the intention-to-treat and per-protocol populations, 22.9% and 31.7% were clinical responders at week 4, respectively, and 25.0% and 36.7% were clinical responders at week 12. Digestive nonintestinal and extra-digestive symptom scores were significantly improved at weeks 4 and 12. Baseline characteristic was not associated with week 12 clinical response; however, clinical response at week 4 was predictive of response at week 12 (OR: 6.5; 95%IC: 2.1–19.8). The most common adverse event was diarrhea inclusive of loose or watery stools (35.4%). Conclusions: Linaclotide improves IBS-C symptoms, including digestive nonintestinal and extra-digestive symptoms. A clinical response at week 4 may predict response at week 12.

show abstract

New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline

Corsetti

Whorwell

2017

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to healthcare services. IBS-D patients represent about one-third of the IBS population and are currently treated with antispasmodics, loperamide, bile acid sequestrants and antidepressants. Alosetron and rifaximin are also available in USA, ramosetron in Japan, Korea and Thailand and ondansetron as an off-label treatment. Areas covered: This article focuses on eluxadoline, a novel pharmacological agent that has recently been approved by both the FDA and EMA for treatment of patients with IBS-D. Expert commentary: The efficacy and safety of eluxadoline in treating bowel habit alterations and pain, both in the short and long-term, make the drug a welcome addition to our therapeutic alternatives in IBS-D. Its positioning in any IBS algorithm will depend on the 'real world' prevalence of the small risk of sphincter of Oddi spasm and mild pancreatitis.

show abstract

The Burden of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In France: A Comparison With The European Results From The Ibis-C Observational Study

Cited by 4 publications

References 0 publications

The global impact of IBS: time to think about IBS-specific models of care?

The global impact of IBS: time to think about IBS-specific models of care?

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms

New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline

Contact Info

Product

Resources

About